每經AI快訊，白云山公(gong)(gong)告，控(kong)股子(zi)公(gong)(gong)司天心制(zhi)藥(yao)(yao)的注(zhu)射用頭孢唑肟鈉(na)(na)通過仿制(zhi)藥(yao)(yao)質量和療效一(yi)致性(xing)評價。2023年注(zhu)射用頭孢唑肟鈉(na)(na)在(zai)(zai)中國公(gong)(gong)立(li)醫院的銷售(shou)額為(wei)(wei)人民(min)(min)幣(bi)38億(yi)元。天心制(zhi)藥(yao)(yao)在(zai)(zai)該(gai)項(xiang)目上已投入(ru)研發費用約(yue)為(wei)(wei)人民(min)(min)幣(bi)272.02萬元，2023年銷售(shou)收(shou)入(ru)為(wei)(wei)人民(min)(min)幣(bi)615.31萬元。通過仿制(zhi)藥(yao)(yao)一(yi)致性(xing)評價有利于提升該(gai)產品的市(shi)場競爭力。